The NAD+ Supplement Aisle Is Getting Crowded. Most of It Won't Get Into Your Cells.

You've been taking 500 mg of nicotinamide riboside every morning for six months. You bought the premium brand, the one with the clinical trial on the label. You feel… roughly the same. Meanwhile, your functional medicine doctor is suggesting IV infusions at $300 a session, a longevity clinic rep is pitching subcutaneous injections, and a new study just dropped arguing that oral precursors barely move the needle on tissue NAD+ levels in humans. The supplement aisle promised cellular rejuvenation. The reality is murkier, and the gap between what's being sold and what's been demonstrated deserves a closer look.

Why NAD+ Became the Longevity Industry's Favourite Molecule

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, central to energy metabolism and the activity of sirtuins — a family of proteins implicated in DNA repair and inflammatory regulation. The mechanism isn't marketing fiction. NAD+ levels measurably decline with age: Camacho-Pereira et al. (2016) established that tissue NAD+ in aged mice ran roughly 50% lower than in young controls, and human studies have since confirmed the same directional trend.

The clinical question is whether supplementing precursors — NR (nicotinamide riboside), NMN (nicotinamide mononucleotide), or IV NAD+ itself — raises tissue levels enough to translate into meaningful biological outcomes in healthy humans. The honest answer right now: sometimes, in some tissues, by varying amounts, with no long-term outcome data in humans.

What the Oral Precursor Trials Actually Showed

The most-cited NR trial in humans, Martens et al. (2018) published in Nature Communications, enrolled 120 overweight, middle-aged adults and found that 1,000 mg/day of NR for six weeks raised whole-blood NAD+ by approximately 60%. That sounds substantial. The same study found no statistically significant change in insulin sensitivity, blood pressure, or several other metabolic markers. Raised blood levels of a molecule and downstream functional benefit are not the same thing.

NMN trials have told a similar story. A 2021 trial by Igarashi et al. found that 250 mg/day of oral NMN improved muscle insulin sensitivity in older women, but the sample enrolled 25 participants — too small to draw broad conclusions. A 2023 study by Yi et al. in Nature Aging involving 80 recreational runners found modest aerobic capacity improvements at 600 mg/day, but the effect size was small and the population was healthy at baseline.

The bioavailability question — whether oral precursors degrade before reaching target tissues — remains unresolved. Some researchers argue NMN is absorbed intact via the intestinal transporter Slc12a8; others contend it converts to niacin before crossing the gut wall. That debate is unresolved as of mid-2026, which means anyone claiming sublingual NMN is "3x more bioavailable" than capsules is selling ahead of the science.

Where IV and Injectable NAD+ Fits

IV NAD+ bypasses the gut entirely, which is why clinics offering infusion protocols price them differently from supplement subscriptions. A typical loading protocol — five sessions of 500–750 mg IV NAD+ over two weeks — runs $1,500 to $2,500 at most US longevity clinics, with monthly maintenance infusions averaging $250–$350 each.

Whether that price differential buys proportionally better outcomes is largely unanswered. IV delivery achieves higher peak plasma concentrations, but NAD+ doesn't cross cell membranes directly — it must be synthesised intracellularly from precursors. That undercuts the "more in the bloodstream means more in the cell" argument for IV versus high-dose oral delivery. Some clinicians counter that higher plasma availability drives more precursor uptake; neither position has long-form human outcome data behind it.

For people exploring clinical protocols rather than pharmacy-aisle supplements, the longevity clinics directory catalogues providers offering structured NAD+ programs alongside bloodwork monitoring — which matters if you're spending at this level.

What Reputable Clinics Are Actually Combining It With

The providers doing this seriously don't prescribe NAD+ protocols in isolation. The working hypothesis in the longevity space is that NAD+ precursors are most likely to show meaningful results when combined with interventions that increase demand for sirtuin activity — resistance training, caloric restriction windows, or compounds like metformin or resveratrol that engage overlapping pathways.

Yucca Health and System Labs, for instance, embed NAD+ support within broader longevity panels that include metabolic markers, hormonal baselines, and periodic reassessment — rather than selling a blanket subscription and calling it anti-ageing medicine. Without baseline and follow-up labs, there is no signal as to whether anything is happening.

If you're in California, longevity clinics in Los Angeles have some of the densest concentrations of these multi-modal protocols, including in-person infusion options for IV loading phases.

The Claims That Deserve Skepticism

Three things being said about NAD+ in 2026 that outrun the evidence:

"It reverses aging." No human trial has demonstrated reversal of biological age using NAD+ precursors as the primary intervention. Epigenetic clock studies showing age regression have generally involved multi-compound protocols — the Horvath group's TRIIM trial used growth hormone, metformin, and DHEA, not NAD+ boosters.

"Our formula raises NAD+ by 300%." Percentage increases in blood NAD+ from a specific product, without specifying measurement methodology, baseline population, and tissue being measured, are nearly meaningless. Whole blood, PBMCs, and muscle tissue give dramatically different readings from the same intervention.

"You need 2,000 mg/day for real effect." No dose-response human trial has established 2,000 mg as a threshold for clinical benefit. The doses showing any effect in human trials top out around 1,000 mg for NR and 600 mg for NMN, with diminishing returns apparent above those levels.

The Honest Takeaway

If you're currently taking oral NR or NMN and feel nothing after 90 days, the trials suggest most people don't experience subjective changes. These molecules are likely safe at studied doses, but "safe" and "effective for longevity" are not the same claim. The clinics worth engaging offer baseline NAD+ metabolomics and a structured reassessment at 12 weeks — not a monthly supplement box with aggressive email marketing. If IV protocols interest you, explore online longevity programs that include monitoring infrastructure, and ask any provider directly which biomarker they're using to measure response. If they can't answer that, the protocol isn't ready for you.

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---